Neo Ivy Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Neo Ivy Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-153,826	Closed	-$2.5M	–	320
2025 Q4	$2.5M	Buy	+153,826	New	+$2.51M	0.39%	103
2022 Q1	–	Sell	-712	Closed	-$20K	–	469
2021 Q4	$20K	Buy	712 +203	+40%	+$6.22K	0.03%	357
2021 Q3	$25K	Buy	509 +316	+164%	+$11.4K	0.03%	377
2021 Q2	$8K	Buy	193 +141	+271%	+$5.48K	0.01%	398
2021 Q1	$2K	Sell	52 -123	-70%	-$6.66K	﹤0.01%	451
2020 Q4	$10K	Sell	175 -4,167	-96%	-$215K	0.01%	380
2020 Q3	$211K	Buy	4,342 +3,833	+753%	+$161K	0.21%	188
2020 Q2	$25K	Sell	509 -1,628	-76%	-$59.4K	0.03%	377
2020 Q1	$59K	Buy	+2,137	New	+$59.6K	0.1%	288

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Neo Ivy Capital Management's ADPT Position: Q1 2026 in Review

Neo Ivy Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2026, closing a stake of 153,826 shares — an estimated $2.5M sold.

Neo Ivy Capital Management first reported a position in ADPT in Q1 2020 and held it in 9 quarters. The position peaked at $2.5M in Q4 2025. 298 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

Neo Ivy Capital Management reported no remaining Adaptive Biotechnologies position as of Q1 2026 after selling out during the quarter.
Neo Ivy Capital Management sold 153,826 Adaptive Biotechnologies shares in Q1 2026, an estimated $2.5M.
Neo Ivy Capital Management first reported a position in Adaptive Biotechnologies in Q1 2020 and held it in 9 quarters.
Neo Ivy Capital Management's Adaptive Biotechnologies position peaked at $2.5M in Q4 2025.
298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.